



Title of Invention

(Below is limited to 1-page only; be careful not to disclose vital technology content. Please delete these words when the document is finished)

PI : Prof. Pi-Hui Liang
Department of Pharmacy, National Taiwan U.

Experience:

Phd, School of pharmacy, National Taiwan University
Research Associate, The Scripps Research Institute
Postdoc, the Genomics Research Center, Academia Sinica

Market Needs:

Market and Demand: Chemotherapy for cancer treatment often results in poor tolerance of patients due to side effects. Targeted therapy for cancer cells will be a trend.

Our Technology:

The binding drug is released in the cancer environment, and the results of animal experiments have proved that the effect on colorectal cancer is obvious

Strength: higher safety and specific to cancer cells.

Competing Products:

SN38, irinotecan

Intellectual Properties:

1. Our research team has a lot of experience in synthesizing precursor drugs, and the development of this small molecule drug linkage is more effective in the treatment of cancer.
2. PCT submission

Contact (do not need to fill out):

Center for Industry-Academia Collaboration, NTU
Tel: 02-3366-9945, E-mail: ordiac@ntu.edu.tw

An interesting photo related to your technology
(be careful not to disclose key technology)